Generic Dovato Availability

Last updated on Jun 11, 2025.

Dovato is a brand name of dolutegravir/lamivudine, approved by the FDA in the following formulation(s):

DOVATO (dolutegravir sodium; lamivudine - tablet;oral)

• Manufacturer: VIIV HLTHCARE
  Approval date: April 8, 2019
  Strength(s): EQ 50MG BASE;300MG ^[RLD]

Is there a generic version of Dovato available?

No. There is currently no therapeutically equivalent version of Dovato available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dovato. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Antiviral therapy
  Patent 11,234,985
  Issued: February 1, 2022
  Inventor(s): Underwood; Mark Richard
  Assignee(s): Viiv Healthcare Company (N/A, N/A)
  

  The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  Patent expiration dates:

  • January 24, 2031
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
    ✓ 
    Drug product
• Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
  Patent 8,129,385
  Issued: March 6, 2012
  Inventor(s): Johns; Brian Alvin et al.
  Assignee(s): Shionogi & Co., Ltd. (Osaka, JP); GlaxoSmithKline LLC (Philadelphia, PA)
  

  The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-di- ones useful as anti-HIV agents. The compounds have the formula: ##STR00001## Z.dbd.O; R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 independently are hydrogen, C.sub.1-C.sub.8 alkyl, (C.sub.6-C.sub.14)aryl-(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or optionally substituted lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

  Patent expiration dates:

  • October 5, 2027
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
  Patent 8129385*PED
  Issued: March 6, 2012
  Inventor(s): Johns; Brian Alvin et al.
  Assignee(s): Shionogi & Co., Ltd. (Osaka, JP); GlaxoSmithKline LLC (Philadelphia, PA)
  

  The present invention is directed to a class of substituted 5-hydroxy-3,4,6,9,9a,10-hexahydro-2H-1-oxa-4a,8a-diaza-anthracene-6,10-di- ones useful as anti-HIV agents. The compounds have the formula: ##STR00001## Z.dbd.O; R.sup.20, R.sup.21, R.sup.22, R.sup.23, R.sup.24 and R.sup.25 independently are hydrogen, C.sub.1-C.sub.8 alkyl, (C.sub.6-C.sub.14)aryl-(C.sub.1-C.sub.8)alkyl, C.sub.6-C.sub.14 aryl, or alkoxy; the stereochemistry of an asymmetric carbon represented by * shows R- or S-configuration, or a mixture thereof; R.sup.X is hydrogen; R.sup.14 is hydrogen or optionally substituted lower alkyl; R.sup.3 is hydrogen; R.sup.1 is hydrogen or lower alkyl; R is halogen; and m is 1, 2 or 3; or a pharmaceutically acceptable salt thereof.

  Patent expiration dates:

  • April 5, 2028
    
    ✓ 
    Pediatric exclusivity
• Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
  Patent 9,242,986
  Issued: January 26, 2016
  Inventor(s): Kawasuji; Takashi et al.
  Assignee(s): SHIONOGI & CO., LTD. (Osaka, JP); ViiV Healthcare Company (Research Triangle Park, NC)
  

  A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##

  Patent expiration dates:

  • December 8, 2029
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
  Patent 9242986*PED
  Issued: January 26, 2016
  Inventor(s): Kawasuji; Takashi et al.
  Assignee(s): SHIONOGI & CO., LTD. (Osaka, JP); ViiV Healthcare Company (Research Triangle Park, NC)
  

  A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-II, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q. ##STR00001##

  Patent expiration dates:

  • June 8, 2030
    
    ✓ 
    Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • April 5, 2027 - NEW PATIENT POPULATION

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer